Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Matthew W Foehr. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Matthew W Foehr har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:OABI / OmniAb, Inc. | President and CEO, Director | 4 341 987 |
US:VKTX / Viking Therapeutics, Inc. | Director | 132 036 |
US:LGND / Ligand Pharmaceuticals Incorporated | 162 187 | |
CLO & Secretary, Director | 0 | |
US:RTTR / Ritter Pharmaceuticals, Inc. | Director | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Matthew W Foehr. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp QLGN / Qualigen Therapeutics, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i QLGN / Qualigen Therapeutics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i QLGN / Qualigen Therapeutics, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp VKTX / Viking Therapeutics, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i QLGN / Qualigen Therapeutics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i QLGN / Qualigen Therapeutics, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-06-30 | VKTX | FOEHR MATTHEW W | 13 000 | 7,3500 | 13 000 | 7,3500 | 95 550 | 330 | 5.19 | −28 080 | −29,39 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Matthew W Foehr som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-26 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 540 540 | 4 341 987 | 14,22 | 1,85 | 999 999 | 8 032 676 | |
2025-04-14 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
M - Exercise | 20 786 | 132 036 | 18,68 | 8,00 | 166 288 | 1 056 288 | |
2025-04-07 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −19 382 | 3 796 236 | −0,51 | 2,00 | −38 764 | 7 592 472 | |
2025-04-07 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 36 458 | 3 815 618 | 0,96 | ||||
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −19 522 | 3 779 160 | −0,51 | 3,67 | −71 646 | 13 869 517 | |
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −13 964 | 3 798 682 | −0,37 | 3,68 | −51 388 | 13 979 150 | |
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 36 458 | 3 812 646 | 0,97 | ||||
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 26 549 | 3 776 188 | 0,71 | ||||
2025-01-22 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −41 811 | 3 749 639 | −1,10 | 3,24 | −135 468 | 12 148 830 | |
2025-01-22 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 77 003 | 3 791 450 | 2,07 | ||||
2024-12-10 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −13 634 | 3 714 447 | −0,37 | 4,13 | −56 308 | 15 340 666 | |
2024-12-10 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 26 555 | 3 728 081 | 0,72 | ||||
2024-11-26 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 68 360 | 3 698 600 | 1,88 | 3,75 | 256 350 | 13 869 750 | |
2024-11-26 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 31 074 | 3 630 240 | 0,86 | 3,68 | 114 352 | 13 359 283 | |
2024-06-27 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 41 015 | 3 599 166 | 1,15 | 3,75 | 153 806 | 13 496 872 | |
2024-06-27 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 18 644 | 3 558 151 | 0,53 | 3,68 | 68 610 | 13 093 996 | |
2024-05-28 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 240 000 | 3 536 665 | 7,28 | 4,42 | 1 059 840 | 15 617 913 | |
2024-04-23 |
|
4/A | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 1 431 618 | 3 296 665 | 76,76 | ||||
2024-04-09 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −18 477 | 3 170 397 | −0,58 | 5,31 | −98 113 | 16 834 808 | |
2024-04-09 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 36 458 | 3 188 874 | 1,16 | ||||
2024-03-29 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 150 391 | 3 152 416 | 5,01 | 3,75 | 563 966 | 11 821 560 | |
2024-03-29 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 93 222 | 3 002 025 | 3,20 | 3,68 | 343 057 | 11 047 452 | |
2024-03-25 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 225 000 | 2 908 803 | 8,38 | 5,19 | 1 167 750 | 15 096 688 | |
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −13 460 | 2 683 803 | −0,50 | 5,54 | −74 568 | 14 868 269 | |
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 26 558 | 2 697 263 | 0,99 | ||||
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −5 459 | 2 670 705 | −0,20 | 5,54 | −30 243 | 14 795 706 | |
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 10 770 | 2 676 164 | 0,40 | ||||
2024-01-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −13 221 | 2 665 394 | −0,49 | 6,25 | −82 631 | 16 658 712 | |
2024-01-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 33 173 | 2 678 615 | 1,25 | ||||
2023-12-13 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 200 000 | 2 645 442 | 8,18 | 5,05 | 1 010 000 | 13 359 482 | |
2023-12-11 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −9 184 | 2 445 442 | −0,37 | 4,85 | −44 542 | 11 860 394 | |
2023-12-11 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 26 556 | 2 454 626 | 1,09 | ||||
2023-11-13 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 95 000 | 2 427 919 | 4,07 | 4,27 | 405 517 | 10 363 815 | |
2023-08-15 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 45 000 | 2 332 919 | 1,97 | 5,48 | 246 600 | 12 784 396 | |
2023-06-12 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 115 000 | 2 574 009 | 4,68 | 4,52 | 519 800 | 11 634 521 | |
2023-05-15 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 440 000 | 2 438 414 | 22,02 | 3,40 | 1 496 000 | 8 290 608 | |
2023-04-11 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 109 375 | 1 998 414 | 5,79 | ||||
2023-02-17 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −4 177 | 1 889 039 | −0,22 | 3,80 | −15 873 | 7 178 348 | |
2023-02-17 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −3 725 | 1 893 216 | −0,20 | 3,80 | −14 155 | 7 194 221 | |
2023-02-17 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −9 184 | 1 896 941 | −0,48 | 3,80 | −34 899 | 7 208 376 | |
2023-01-05 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 79 665 | 1 906 125 | 4,36 | ||||
2022-12-30 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −11 624 | 1 826 460 | −0,63 | 3,66 | −42 544 | 6 684 844 | |
2022-12-14 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 150 000 | 1 838 084 | 8,89 | 3,77 | 564 765 | 6 920 570 | |
2022-12-05 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −17 266 | 1 688 084 | −1,01 | 3,35 | −57 841 | 5 655 081 | |
2022-12-01 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 300 000 | 1 705 350 | 21,35 | 3,39 | 1 016 340 | 5 777 385 | |
2022-11-09 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 100 000 | 1 405 350 | 7,66 | 2,76 | 276 160 | 3 881 015 | |
2022-11-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | −20 304 | 162 187 | −11,13 | ||||
2022-11-03 |
|
4 | NONE |
OmniAb Operations, Inc.
Common Stock |
D - Sale to Issuer | −212 362 | 0 | −100,00 | ||||
2022-11-03 |
|
4 | NONE |
OmniAb Operations, Inc.
Common Stock |
A - Award | 26 193 | 212 362 | 14,07 | ||||
2022-11-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 1 305 350 | 1 305 350 | |||||
2022-06-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 137 | 182 491 | 5,27 | ||||
2022-05-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 500 | 173 354 | 1,46 | 82,76 | 206 910 | 14 347 436 | |
2022-05-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 34 214 | 34 214 | |||||
2022-05-03 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
P - Purchase | 45 000 | 111 250 | 67,92 | 2,47 | 111 195 | 274 899 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 090 | 170 854 | −0,63 | 123,68 | −134 811 | 21 131 223 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 222 | 171 944 | −0,71 | 123,68 | −151 137 | 21 266 034 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 234 | 173 166 | −0,71 | 123,68 | −152 621 | 21 417 171 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −3 188 | 174 400 | −1,80 | 113,68 | −362 412 | 19 825 792 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 937 | 177 588 | −1,08 | 113,68 | −220 198 | 20 188 204 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 396 | 179 525 | 4,30 | ||||
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 604 | 172 129 | 3,37 | ||||
2022-01-05 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 22 000 | 22 000 | |||||
2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 028 | 24 348 | −4,05 | ||||
2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −11 160 | 0 | −100,00 | ||||
2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −11 160 | 166 525 | −6,28 | 163,02 | −1 819 255 | 27 146 189 | |
2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 11 160 | 177 685 | 6,70 | 21,92 | 244 627 | 3 894 855 | |
2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 028 | 166 525 | 0,62 | 100,38 | 103 191 | 16 715 780 | |
2021-08-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 142 | 25 938 | −4,22 | ||||
2021-08-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −8 840 | 11 160 | −44,20 | ||||
2021-08-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 142 | 165 497 | 0,69 | 85,79 | 97 972 | 14 197 988 | |
2021-08-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −8 840 | 164 355 | −5,10 | 109,67 | −969 507 | 18 025 257 | |
2021-08-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 840 | 173 195 | 5,38 | 21,92 | 193 773 | 3 796 434 | |
2021-06-10 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
P - Purchase | 20 000 | 66 250 | 43,24 | 5,69 | 113 800 | 376 962 | |
2021-06-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 755 | 40 358 | −4,17 | ||||
2021-06-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 755 | 164 355 | 1,08 | 56,26 | 98 736 | 9 246 612 | |
2021-06-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
G - Gift | −2 500 | 162 600 | −1,51 | ||||
2021-03-25 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Warrants (Right to Buy) |
X - Other | −20 000 | 0 | −100,00 | ||||
2021-03-25 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
X - Other | 20 000 | 46 250 | 76,19 | 1,50 | 30 000 | 69 375 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 222 | 165 100 | −0,73 | 172,46 | −210 746 | 28 473 146 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 235 | 166 322 | −0,74 | 172,46 | −212 988 | 28 683 892 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −641 | 167 557 | −0,38 | 172,46 | −110 547 | 28 896 880 | |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 000 | 63 210 | −1,56 | ||||
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −44 547 | 20 000 | −69,01 | ||||
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −44 547 | 168 198 | −20,94 | 176,86 | −7 878 582 | 29 747 498 | |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 44 547 | 212 745 | 26,48 | 21,92 | 976 470 | 4 663 370 | |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 000 | 168 198 | 0,60 | 74,42 | 74 420 | 12 517 295 | |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 13 136 | 13 136 | |||||
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 595 | 167 198 | 4,11 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 272 | 160 603 | −1,39 | 156,01 | −354 455 | 25 055 674 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 604 | 162 875 | 3,56 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 053 | 157 271 | −0,67 | 156,01 | −164 279 | 24 535 849 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 911 | 158 324 | 1,87 | ||||
2021-01-06 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 22 000 | 22 000 | |||||
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −78 | 64 547 | −0,12 | |||
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −78 | 155 413 | −0,05 | 110,89 | −8 649 | 17 233 748 |
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 78 | 155 491 | 0,05 | 21,92 | 1 710 | 3 408 363 |
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −790 | 64 210 | −1,22 | ||||
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −7 225 | 0 | −100,00 | |||
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 225 | 155 413 | −4,44 | 112,88 | −815 541 | 17 542 646 |
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 7 225 | 162 638 | 4,65 | 14,47 | 104 546 | 2 353 372 |
2020-08-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 790 | 155 413 | 0,51 | 74,42 | 58 792 | 11 565 835 | |
2020-06-30 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
S - Sale | −13 000 | 26 250 | −33,12 | 7,35 | −95 550 | 192 938 | |
2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −642 | 122 727 | −0,52 | 120,86 | −77 592 | 14 832 785 | |
2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 246 | 123 369 | −1,00 | 120,86 | −150 592 | 14 910 377 | |
2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −938 | 124 615 | −0,75 | 120,86 | −113 367 | 15 060 969 | |
2020-04-23 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Warrant Shares (right to buy) |
D - Sale to Issuer | −38 461 | 0 | −100,00 | ||||
2020-04-23 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
A - Award | 38 461 | 138 635 | 38,39 | ||||
2020-04-23 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Series B convertible preferred stock |
C - Conversion | −100 | 0 | −100,00 | ||||
2020-04-23 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
C - Conversion | 76 923 | 100 174 | 330,84 | ||||
2020-03-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 000 | 64 625 | −3,00 | ||||
2020-03-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 000 | 157 449 | 1,29 | 21,92 | 43 840 | 3 451 282 | |
2020-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 706 | 66 625 | −2,50 | ||||
2020-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −7 225 | 7 225 | −50,00 | |||
2020-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 706 | 155 449 | 1,11 | 21,92 | 37 396 | 3 407 442 | |
2020-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 225 | 153 743 | −4,49 | 110,00 | −794 750 | 16 911 730 |
2020-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 7 225 | 160 968 | 4,70 | 14,47 | 104 546 | 2 329 207 |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 170 | 153 743 | −0,76 | 97,23 | −113 759 | 14 948 432 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −447 | 154 913 | −0,29 | 97,23 | −43 462 | 15 062 191 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −869 | 155 360 | −0,56 | 97,23 | −84 493 | 15 105 653 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −7 225 | 14 450 | −33,33 | |||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 225 | 156 229 | −4,42 | 95,84 | −692 467 | 14 973 487 |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 7 225 | 163 454 | 4,62 | 14,47 | 104 546 | 2 365 179 |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 33 210 | 33 210 | |||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −496 | 68 331 | −0,72 | ||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 396 | 156 229 | 4,97 | ||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 496 | 148 833 | 0,33 | 21,92 | 10 872 | 3 262 419 | |
2020-01-17 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Non-qualified Stock Option (Right to Buy) |
A - Award | 12 000 | 12 000 | |||||
2020-01-03 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 22 000 | 22 000 | |||||
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 444 | 148 337 | −0,96 | 105,87 | −152 876 | 15 704 438 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 913 | 149 781 | 1,98 | ||||
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 210 | 146 868 | −1,48 | 105,87 | −233 973 | 15 548 915 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 4 458 | 149 078 | 3,08 | ||||
2019-11-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 001 | 68 827 | −1,43 | ||||
2019-11-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 001 | 144 620 | 0,70 | 21,92 | 21 942 | 3 170 070 | |
2019-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 005 | 69 828 | −1,42 | ||||
2019-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 005 | 143 619 | 0,70 | 21,92 | 22 030 | 3 148 128 | |
2019-08-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 163 | 70 833 | −1,62 | ||||
2019-08-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 163 | 142 614 | 0,82 | 21,92 | 25 493 | 3 126 099 | |
2019-06-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 004 | 71 996 | −1,38 | ||||
2019-06-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 004 | 141 451 | 0,71 | 21,92 | 22 008 | 3 100 606 | |
2019-03-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −14 894 | 15 001 | −49,82 | ||||
2019-03-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 14 894 | 140 447 | 11,86 | 9,97 | 148 493 | 1 400 257 | |
2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 34 181 | 34 181 | |||||
2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 472 | 125 553 | 6,33 | ||||
2019-02-08 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Non-qualified Stock Option (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 284 | 118 081 | −1,08 | 111,78 | −143 526 | 13 199 094 | |
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 284 | 118 081 | −1,08 | 111,78 | −143 526 | 13 199 094 | |
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 715 | 119 365 | 3,21 | ||||
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 547 | 116 934 | 3,13 | ||||
2019-01-03 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 22 000 | 22 000 | |||||
2018-12-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −7 999 | 29 895 | −21,11 | ||||
2018-12-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 7 999 | 113 387 | 7,59 | 9,97 | 79 750 | 1 130 468 | |
2018-11-07 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Warrant Shares (right to buy) |
P - Purchase | 38 461 | 38 461 | |||||
2018-11-07 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Series B convertible preferred stock |
P - Purchase | 100 | 100 | |||||
2018-10-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −12 000 | 21 675 | −35,63 | |||
2018-10-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 088 | 37 894 | −5,22 | ||||
2018-10-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −12 000 | 105 388 | −10,22 | 273,88 | −3 286 560 | 28 863 665 |
2018-10-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 000 | 117 388 | 11,39 | 14,47 | 173 640 | 1 698 604 |
2018-10-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 088 | 105 388 | 2,02 | 9,97 | 20 817 | 1 050 718 | |
2018-09-19 |
|
4/A | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
P - Purchase | 19 751 | 23 251 | 564,31 | 2,04 | 40 292 | 47 432 | |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −12 000 | 33 675 | −26,27 | |||
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 044 | 39 982 | −2,54 | ||||
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −12 000 | 103 300 | −10,41 | 255,01 | −3 060 082 | 26 342 202 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 000 | 115 300 | 11,62 | 14,47 | 173 640 | 1 668 391 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 044 | 103 300 | 1,02 | 9,97 | 10 409 | 1 029 901 | |
2018-08-20 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
P - Purchase | 19 751 | 54 751 | 56,43 | 2,04 | 40 292 | 111 692 | |
2018-05-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −8 881 | 45 675 | −16,28 | ||||
2018-05-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 055 | 41 026 | −2,51 | ||||
2018-05-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 055 | 102 256 | 1,04 | 9,97 | 10 518 | 1 019 492 | |
2018-05-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −8 881 | 101 201 | −8,07 | 167,63 | −1 488 687 | 16 963 919 | |
2018-05-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 881 | 110 082 | 8,78 | 14,47 | 128 508 | 1 592 887 | |
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 457 | 101 201 | −1,42 | 165,87 | −241 673 | 16 786 210 | |
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 940 | 102 658 | 2,95 | ||||
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 20 274 | 20 274 | |||||
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 883 | 99 718 | 4,05 | ||||
2018-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −5 444 | 54 556 | −9,07 | ||||
2018-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 004 | 42 081 | −2,33 | ||||
2018-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 444 | 95 835 | −5,38 | 152,98 | −832 824 | 14 660 848 | |
2018-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 5 444 | 101 279 | 5,68 | 14,47 | 78 775 | 1 465 507 | |
2018-02-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 004 | 95 835 | 1,06 | 9,97 | 10 010 | 955 475 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 246 | 94 831 | −1,30 | 157,18 | −195 846 | 14 905 537 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −906 | 96 077 | −0,93 | 157,18 | −142 405 | 15 101 383 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 511 | 96 983 | −1,53 | 157,18 | −237 499 | 15 243 788 | |
2018-01-25 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Non-qualified Stock Option (Right to Buy) |
A - Award | 30 000 | 30 000 | |||||
2018-01-03 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16 000 | 16 000 | |||||
2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 971 | 98 494 | −2,93 | 138,66 | −411 959 | 13 657 178 | |
2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 695 | 101 465 | 5,95 | ||||
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −850 | 43 085 | −1,93 | ||||
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −6 100 | 43 935 | −12,19 | ||||
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 850 | 95 770 | 0,90 | 9,97 | 8 474 | 954 827 | |
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 100 | 94 920 | −6,04 | 127,51 | −777 824 | 12 103 449 | |
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 100 | 101 020 | 6,43 | 9,97 | 60 817 | 1 007 169 | |
2017-05-18 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
P - Purchase | 18 000 | 35 000 | 105,88 | 0,62 | 11 155 | 21 690 | |
2017-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 200 | 50 035 | −4,21 | ||||
2017-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 200 | 94 920 | 2,37 | 9,97 | 21 934 | 946 352 | |
2017-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −5 621 | 52 235 | −9,72 | ||||
2017-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 621 | 92 720 | −5,72 | 112,20 | −630 650 | 10 402 757 | |
2017-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 5 621 | 98 341 | 6,06 | 9,97 | 56 041 | 980 460 | |
2017-03-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 000 | 57 856 | −3,34 | ||||
2017-03-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 000 | 92 720 | 2,20 | 9,97 | 19 940 | 924 418 | |
2017-03-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −6 879 | 59 856 | −10,31 | ||||
2017-03-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 879 | 90 720 | −7,05 | 103,39 | −711 214 | 9 379 459 | |
2017-03-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 879 | 97 599 | 7,58 | 9,97 | 68 584 | 973 062 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 25 376 | 25 376 | |||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 544 | 90 720 | 9,07 | ||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 733 | 83 176 | −3,18 | 100,38 | −274 339 | 8 349 207 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 239 | 85 909 | 6,49 | ||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −725 | 80 670 | −0,89 | 104,28 | −75 603 | 8 412 268 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 642 | 81 395 | −1,98 | 104,28 | −171 228 | 8 487 871 | |
2017-01-05 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16 000 | 16 000 | |||||
2016-11-30 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Stock Option (2015 Equity Incentive Plan) |
A - Award | 7 000 | 7 000 | |||||
2016-11-15 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
P - Purchase | 13 000 | 39 250 | 49,52 | 1,21 | 15 678 | 47 336 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −4 125 | 66 735 | −5,82 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 125 | 83 037 | 5,23 | 9,97 | 41 126 | 827 879 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −12 500 | 70 860 | −15,00 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −12 500 | 78 912 | −13,67 | 122,14 | −1 526 750 | 9 638 312 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12 500 | 91 412 | 15,84 | 9,97 | 124 625 | 911 378 | |
2016-04-13 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Warrants (Right to Buy) |
P - Purchase | 20 000 | 20 000 | 0,01 | 200 | 200 | ||
2016-04-13 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 |
P - Purchase | 20 000 | 26 250 | 320,00 | 1,24 | 24 800 | 32 550 | |
2016-03-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 250 | 83 360 | −2,63 | ||||
2016-03-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −6 400 | 85 610 | −6,96 | ||||
2016-03-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 250 | 78 912 | 2,93 | 9,97 | 22 432 | 786 753 | |
2016-03-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 400 | 76 662 | −7,71 | 96,70 | −618 880 | 7 413 215 | |
2016-03-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 400 | 83 062 | 8,35 | 9,97 | 63 808 | 828 128 | |
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 642 | 76 662 | −2,10 | 85,97 | −141 163 | 6 590 632 | |
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 27 080 | 27 080 | |||||
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 676 | 78 304 | 7,82 | ||||
2016-01-11 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
P - Purchase | 13 000 | 17 000 | 325,00 | 1,64 | 21 320 | 27 880 | |
2016-01-06 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16 000 | 16 000 | |||||
2015-10-15 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Stock Option (2015 Equity Incentive Plan) |
A - Award | 10 000 | 10 000 | |||||
2015-06-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 500 | 92 010 | −2,65 | ||||
2015-06-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 72 628 | 3,56 | 9,97 | 24 925 | 724 101 | |
2015-06-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −12 500 | 94 510 | −11,68 | |||
2015-06-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −12 500 | 70 128 | −15,13 | 100,97 | −1 262 125 | 7 080 824 |
2015-06-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 500 | 82 628 | 17,82 | 9,97 | 124 625 | 823 801 |
2015-06-25 |
|
4 | RTTR |
RITTER PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4 000 | 4 000 | 5,00 | 20 000 | 20 000 | ||
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −2 000 | 107 010 | −1,83 | ||||
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −23 046 | 109 010 | −17,45 | |||
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 000 | 70 128 | 2,94 | 9,97 | 19 940 | 699 176 | |
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −3 355 | 68 128 | −4,69 | 97,47 | −327 012 | 6 640 436 |
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −15 145 | 71 483 | −17,48 | 96,43 | −1 460 432 | 6 893 106 |
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −4 546 | 86 628 | −4,99 | 95,77 | −435 370 | 8 296 364 |
2015-06-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 23 046 | 91 174 | 33,83 | 9,97 | 229 769 | 909 005 |
2015-05-05 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share |
P - Purchase | 6 250 | 6 250 | 8,00 | 50 000 | 50 000 | ||
2015-04-30 |
|
4 | VKTX |
Viking Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 20 786 | 20 786 | |||||
2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 42 113 | 42 113 | 56,26 | 2 369 277 | 2 369 277 | ||
2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 13 112 | 68 128 | 23,83 | ||||
2015-01-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 46 | 55 016 | 0,08 | 45,23 | 2 081 | 2 488 291 | |
2014-10-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 000 | 132 056 | −0,75 | ||||
2014-10-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 000 | 54 970 | 1,85 | 9,97 | 9 970 | 548 051 | |
2014-10-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 85 | 53 970 | 0,16 | 44,91 | 3 817 | 2 423 793 | |
2014-07-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 428 | 53 885 | 0,80 | 43,79 | 18 743 | 2 359 732 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −22 500 | 133 056 | −14,46 | |||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −3 444 | 155 556 | −2,17 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −22 500 | 53 457 | −29,62 | 79,54 | −1 789 650 | 4 251 970 |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 22 500 | 75 957 | 42,09 | 9,97 | 224 325 | 757 291 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 3 444 | 53 457 | 6,89 | 9,97 | 34 337 | 532 966 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 000 | 65 000 | 18,18 | 74,42 | 744 200 | 4 837 300 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 000 | 65 000 | 18,18 | 74,42 | 744 200 | 4 837 300 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 45 000 | 45 000 | 74,42 | 3 348 900 | 3 348 900 | ||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 000 | 50 013 | 11,11 | ||||
2014-01-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 84 | 45 013 | 0,19 | 33,92 | 2 849 | 1 526 616 | |
2013-12-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −6 000 | 159 000 | −3,64 | ||||
2013-12-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 000 | 44 929 | −11,78 | 53,40 | −320 400 | 2 399 209 | |
2013-12-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 000 | 50 929 | 13,35 | 9,97 | 59 820 | 507 762 | |
2013-07-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 059 | 44 929 | 2,41 | 17,36 | 18 384 | 779 967 | |
2013-06-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 8 333 | 43 870 | 23,45 | ||||
2013-06-04 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 51 546 | 51 546 | 9,97 | 513 914 | 513 914 | ||
2013-06-04 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 16 667 | 16 667 | |||||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 64 625 | 64 625 | 21,92 | 1 416 580 | 1 416 580 | ||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
A - Award | 8 375 | 8 375 | 21,92 | 183 580 | 183 580 | ||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 000 | 43 870 | 15,84 | ||||
2012-12-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 370 | 37 870 | 0,99 | 17,99 | 6 656 | 681 224 | |
2012-07-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 1 250 | 37 500 | 3,45 | 10,12 | 12 654 | 379 631 | |
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 60 000 | 60 000 | 14,47 | 868 200 | 868 200 | ||
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 10 000 | 36 250 | 38,10 | ||||
2012-01-06 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 1 250 | 26 250 | 5,00 | 10,09 | 12 612 | 264 849 |